Non Small Cell Lung Cancer Clinical Trials in Columbus, Ohio

24 studies are recruiting for non small cell lung cancer in Columbus, Ohio right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

Studies now recruiting

  1. Clinical Study of Ivonescimab for First-line Treatment of Metastatic NSCLC Patients With High PD-L1

    Clinical study of ivonescimab for first-line treatment of metastatic NSCLC patients with high PD-L1. Evaluating overall survival and progression free survival.

    Stage
    Phase 3
    Ages
    18 and older
    Site
    Clinical Study Sites, Columbus, Ohio
    Locations
    285 in total
    Run by
    Summit Therapeutics

    See if you can join NCT06767514 on ClinicalTrials.gov

  2. Dabrafenib and/or Trametinib Rollover Study

    This study is to provide access for patients who are receiving treatment with dabrafenib and/or trametinib in a Novartis-sponsored Oncology Global Development, Global Medical Affairs or a former GSK-sponsored study who have fulfilled the requirements for the primary objective, and who are judged by…

    Stage
    Phase 4
    Ages
    18 to 100
    Site
    James Cancer Hospital and Solove Research Institute Ohio State, Columbus, Ohio
    Locations
    34 in total
    Run by
    Novartis Pharmaceuticals

    See if you can join NCT03340506 on ClinicalTrials.gov

  3. FiH Study to Investigate Safety, PK and Efficacy of the NaPi2b ADC TUB-040 in Patients With PROC or r/r Adenocarcinoma NSCLC

    The purpose of this multicenter, open label trial (NAPISTAR 1-01) is to evaluate the safety/tolerability, pharmacokinetics and preliminary efficacy of TUB-040 and to find the best dose of TUB-040 in participants with ovarian cancer and Non Small Cell Lung Cancer. TUB-040 is an antibody-drug-conjuga…

    Stage
    Phase 1
    Ages
    18 and older
    Site
    Ohio State University, Columbus, Ohio
    Locations
    29 in total
    Run by
    Tubulis GmbH

    See if you can join NCT06303505 on ClinicalTrials.gov

  4. A Study of Multiple Therapies in Biomarker-selected Participants With Resectable Stages IB-III Non-small Cell Lung Cancer (NSCLC)

    This trial will evaluate the efficacy and safety of various therapies in participants with Stage IB, IIA, IIB, IIIA, or selected IIIB resectable and untreated NSCLC tumors that meet protocol-specified biomarker criteria.

    Stage
    Phase 2
    Ages
    18 and older
    Site
    Ohio State University, Columbus, Ohio
    Locations
    38 in total
    Run by
    Genentech, Inc.

    See if you can join NCT04302025 on ClinicalTrials.gov

  5. A Study of LY4050784 in Participants With Advanced or Metastatic Solid Tumors

    The main purpose of this study is to find out whether the study drug, LY4050784, is safe, tolerable and effective in participants alone or in combination with other anticancer agents. In addition, with locally advanced or metastatic solid tumors with a BRG1 (Brahma-related gene 1, also known as SMA…

    Stage
    Phase 1
    Ages
    18 and older
    Site
    Ohio State University Hospital, Columbus, Ohio
    Locations
    33 in total
    Run by
    Eli Lilly and Company

    See if you can join NCT06561685 on ClinicalTrials.gov

  6. A Study Evaluating the Efficacy and Safety of Divarasib and Pembrolizumab Versus Pembrolizumab and Pemetrexed and Carboplatin or Cisplatin in Participants With Previously Untreated, KRAS G12C-Mutated, Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer

    The purpose of this study is to evaluate the efficacy and safety of divarasib and pembrolizumab compared with pembrolizumab and pemetrexed and carboplatin or cisplatin, for the first-line treatment of adult participants with KRAS G12C-mutated, advanced or metastatic non squamous non-small cell lung…

    Stage
    Phase 3
    Ages
    18 and older
    Site
    Ohio State University, Columbus, Ohio
    Locations
    280 in total
    Run by
    Hoffmann-La Roche

    See if you can join NCT06793215 on ClinicalTrials.gov

  7. Solid Tumor Analysis for HLA Loss of Heterozygosity (LOH) and Apheresis for CAR T- Cell Manufacturing

    Objective: To collect information on how often a solid tumor cancer might lose the Human Leukocyte Antigen (HLA) by next generation sequencing and perform apheresis to collect and store an eligible participant's own T cells for future use to make CAR T-Cell therapy for their disease treatment. Desi…

    Stage
    Not phased
    Ages
    18 and older
    Site
    The Ohio State University Comprehensive Cancer Center, Columbus, Ohio
    Locations
    16 in total
    Run by
    A2 Biotherapeutics Inc.

    See if you can join NCT04981119 on ClinicalTrials.gov

  8. Study to Evaluate Efficacy and Safety of Firmonertinib Compared With Investigator's Choice of EGFR Inhibitor as First-Line Treatment in Participants Who Have Locally Advanced or Metastatic NSCLC With EGFR P-Loop and Alpha C-Helix Compressing (PACC) Uncommon Mutations

    Global, Phase 3, randomized, multicenter, open-label study evaluating the efficacy and safety of firmonertinib at a dose level of 240 mg QD compared to investigator's choice of osimertinib (80 mg QD) or afatinib (40 mg QD) in participants who have locally advanced or metastatic NSCLC with EGFR PACC…

    Stage
    Phase 3
    Ages
    18 and older
    Site
    Ohio State University Hospitals, Columbus, Ohio
    Locations
    118 in total
    Run by
    ArriVent BioPharma, Inc.

    See if you can join NCT07185997 on ClinicalTrials.gov

  9. Neladalkib (NVL-655) for TKI-naive Patients With Advanced ALK-Positive NSCLC

    Multicenter, randomized, controlled, open-label, Phase 3 study designed to demonstrate that neladalkib (NVL-655) is superior to alectinib in prolonging progression-free survival (PFS) in patients with treatment-naïve, Anaplastic Lymphoma Kinase (ALK) positive, advanced Non-Small Cell Lung Cancer (N…

    Stage
    Phase 3
    Ages
    18 and older
    Site
    The Ohio State University, Columbus, Ohio
    Locations
    158 in total
    Run by
    Nuvalent Inc.

    See if you can join NCT06765109 on ClinicalTrials.gov

  10. Study of Izalontamab Brengitecan (BMS-986507) Versus Platinum-Pemetrexed for EGFR-mutated Non-small Cell Lung Cancer After Failure of EGFR TKI Therapy (IZABRIGHT-Lung01)

    A Study of Izalontamab Brengitecan (BMS-986507) versus Platinum-Pemetrexed for EGFR-mutated Non-small Cell Lung Cancer after failure of EGFR TKI Therapy

    Stage
    Phase 2
    Ages
    18 and older
    Site
    The James Cancer Hospital and Solove Research Institute at The Ohio State University Comprehensive C, Columbus, Ohio
    Locations
    186 in total
    Run by
    Bristol-Myers Squibb

    See if you can join NCT07100080 on ClinicalTrials.gov

  11. A Study of Intismeran Autogene (V940) Plus Pembrolizumab (MK-3475) Versus Placebo Plus Pembrolizumab in Participants With Non-small Cell Lung Cancer (V940-002)

    The goal of this study is to evaluate intismeran autogene plus pembrolizumab versus placebo plus pembrolizumab for the adjuvant treatment of margin negative, completely resected Stage II, IIIA, IIIB (with nodal involvement [N2]) non-small cell lung cancer (NSCLC). The primary hypothesis is that int…

    Stage
    Phase 3
    Ages
    18 and older
    Site
    OSU Brain and Spine Hospital ( Site 0016), Columbus, Ohio
    Locations
    229 in total
    Run by
    Merck Sharp & Dohme LLC

    See if you can join NCT06077760 on ClinicalTrials.gov

  12. Phase III, Open-label, Study of First-line Dato-DXd in Combination With Rilvegostomig for Advanced Non-squamous NSCLC With High PD-L1 Expression (TC ≥ 50%) and Without Actionable Genomic Alterations

    The purpose of this study is to evaluate efficacy and safety of Dato-DXd in combination with rilvegostomig or rilvegostomig monotherapy compared with pembrolizumab monotherapy as a first line therapy in participants with locally advanced or metastatic non-squamous NSCLC with high PD-L1 expression (…

    Stage
    Phase 3
    Ages
    18 and older
    Site
    Research Site, Columbus, Ohio
    Locations
    287 in total
    Run by
    AstraZeneca

    See if you can join NCT06357533 on ClinicalTrials.gov

  13. Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001)

    This study will test the safety, including side effects, and determine the characteristics of a drug called Rina-S in participants with solid tumors. Participants will have solid tumor cancer that has spread through the body (metastatic) or cannot be removed with surgery (unresectable).

    Stage
    Phase 1
    Ages
    18 and older
    Site
    Ohio State University Comprehensive Cancer Center (OSUCCC)- The James Cancer Hospital and Solove Research Institute, Columbus, Ohio
    Locations
    66 in total
    Run by
    Genmab

    See if you can join NCT05579366 on ClinicalTrials.gov

  14. Clinical Trial Evaluating the Safety, Tolerability and Preliminary Efficacy of BNT116 Alone and in Combinations in Patients With Advanced Non-small Cell Lung Cancer

    This first-in-human (FIH) study for BNT116 aims to establish the safety profile and a safe dose for BNT116 monotherapy as well as for BNT116 in combination with approved medicinal products and/or in combination with investigational medicinal products (IMPs) including, but not limited to, cemiplimab…

    Stage
    Phase 1
    Ages
    18 and older
    Site
    Ohio State University, Columbus, Ohio
    Locations
    45 in total
    Run by
    BioNTech SE

    See if you can join NCT05142189 on ClinicalTrials.gov

  15. Study of STK-012 Alone and With Other Treatments in Patients With Advanced Lung Cancer and Other Cancers

    This is a phase 1/2, multicenter, open-label study. The phase 1 portion is a dose escalation and expansion study of STK-012 as monotherapy and in combination therapy in patients with selected advanced solid tumors. The phase 2 portion is a randomized study of STK-012 in combination with standard of…

    Stage
    Phase 1
    Ages
    18 and older
    Site
    The James Cancer Hospital and Solove Research Institute, Columbus, Ohio
    Locations
    47 in total
    Run by
    Synthekine

    See if you can join NCT05098132 on ClinicalTrials.gov

  16. Personalized Cancer Vaccine (PCV) Strategy in Patients With Solid Tumors and Molecular Residual Disease

    This is a phase 1 clinical trial to evaluate the safety, feasibility and immunogenicity of a personalized cancer vaccine strategy in patients with solid tumors and molecular residual disease. The hypothesis of the trial is that synthetic long peptide personalized cancer vaccines will be safe and ca…

    Stage
    Phase 1
    Ages
    18 and older
    Site
    Ohio State University, Columbus, Ohio
    Locations
    3 in total
    Run by
    Washington University School of Medicine

    See if you can join NCT06529822 on ClinicalTrials.gov

  17. Safety and Efficacy of OBX-115 in Advanced Solid Tumors

    This is a study to investigate the safety and efficacy of an investigational OBX-115 regimen in adult participants with advanced solid tumors.

    Stage
    Phase 1
    Ages
    18 and older
    Site
    The Ohio State University, Columbus, Ohio
    Locations
    10 in total
    Run by
    Obsidian Therapeutics, Inc.

    See if you can join NCT06060613 on ClinicalTrials.gov

  18. Radiotherapy to Block Oligoprogression In Metastatic Non-Small-Cell Lung Cancer

    This study is being done to answer the following question: Can the chance of lung cancer growing or spreading be lowered by adding targeted radiotherapy to the usual combination of drugs? This study is being done to find out if this approach is better or worse than the usual approach for lung cance…

    Stage
    Phase 3
    Ages
    18 and older
    Site
    Ohio State University Comprehensive Cancer Center, Columbus, Ohio
    Locations
    75 in total
    Run by
    Canadian Cancer Trials Group

    See if you can join NCT06686771 on ClinicalTrials.gov

  19. A Study to Evaluate the Safety and Efficacy of Mesothelin-Targeting Logic-gated CAR T, in Participants With Solid Tumors That Express MSLN and Have Lost HLA-A*02 Expression

    The goal of this study is to test autologous logic-gated Tmod™ CAR T-cell products in subjects with solid tumors including colorectal cancer (CRC), pancreatic cancer (PANC), non-small cell lung cancer (NSCLC), ovarian cancer (OVCA), mesothelioma (MESO), and other solid tumors that express mesotheli…

    Stage
    Phase 1
    Ages
    18 and older
    Site
    The Ohio State University Comprehensive Cancer Center, Columbus, Ohio
    Locations
    12 in total
    Run by
    A2 Biotherapeutics Inc.

    See if you can join NCT06051695 on ClinicalTrials.gov

  20. JoLT-Ca Sublobar Resection (SR) Versus Stereotactic Ablative Radiotherapy (SAbR) for Lung Cancer

    To Determine if SAbR improves survival over SR in High Risk Operable Stage I NSCLC

    Stage
    Phase 3
    Ages
    18 and older
    Site
    Ohio State University Wexner Medical Center, Columbus, Ohio
    Locations
    50 in total
    Run by
    University of Texas Southwestern Medical Center

    See if you can join NCT02468024 on ClinicalTrials.gov

  21. Safety and Tolerability of TNG456 Alone and in Combination With Abemaciclib in Patients With Solid Tumors With MTAP Loss

    This is a first in human study of TNG456 alone and in combination with abemaciclib in patients with advanced or metastatic solid tumors known to have an MTAP loss. The first part of the study is an open-label, dose escalation and the second part is an open label dose expansion in specific solid tum…

    Stage
    Phase 1
    Ages
    18 and older
    Site
    Ohio State University Comprehensive Cancer Center, Columbus, Ohio
    Locations
    15 in total
    Run by
    Tango Therapeutics, Inc.

    See if you can join NCT06810544 on ClinicalTrials.gov

  22. Adagrasib + SRS for Patients With Metastatic KRAS G12C-mutated NSCLC With Untreated Brain Metastases

    This is a single arm phase 2 trial is to evaluate the efficacy of SRS plus adagrasib for the treatment of brain metastases for patients with KRAS G12C-mutated non-small cell lung cancer (NSCLC). A total of 30 patients will be enrolled on this study.

    Stage
    Phase 2
    Ages
    18 and older
    Site
    Ohio State University Comprehensive Cancer Center, Columbus, Ohio
    Locations
    3 in total
    Run by
    Ryan Gentzler, MD

    See if you can join NCT06248606 on ClinicalTrials.gov

  23. GEMINI-NSCLC: NSCLC Biomarker Study

    GEMINI NSCLC Study is a non-interventional study that will be collecting clinical and molecular health information from patients with NSCLC who will receive longitudinal blood collection in addition to their standard of care therapy and disease surveillance with the goals of identifying the molecul…

    Stage
    Not phased
    Ages
    18 and older
    Site
    Ohio State University, Columbus, Ohio
    Locations
    58 in total
    Run by
    Tempus AI

    See if you can join NCT05236114 on ClinicalTrials.gov

  24. SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry

    International registry for cancer patients evaluating the feasibility and clinical utility of an Artificial Intelligence-based precision oncology clinical trial matching tool, powered by a virtual tumor boards (VTB) program, and its clinical impact on pts with advanced cancer to facilitate clinical…

    Stage
    Not phased
    Ages
    Any age
    Site
    Massive Bio SYNERGY-AI site, Columbus, Ohio
    Locations
    68 in total
    Run by
    Massive Bio, Inc.

    See if you can join NCT03452774 on ClinicalTrials.gov

How to read this page. Every study here comes from ClinicalTrials.gov, the public registry that research teams are required to file with. We have summarised each one in plain language and shown where it is running. We have not changed what any study says it is doing.

What TrialBoost is. We help people find research that might suit them, and, if they ask us to, we pass their details to the research team running it. We are not a doctor, a research site, or a study sponsor, and we do not decide who takes part in anything. Joining costs nothing and you can change your mind at any point.

Paid placement. Some studies pay us when someone asks to be connected to them. Those are labelled Sponsored wherever they appear, and they only appear when they match what you were actually looking for.